ReviewJHEP reports : innovation in hepatology2023
Health inequalities in the management of chronic hepatitis B virus infection in patients from sub-Saharan Africa in high-income countries.
Review in JHEP reports : innovation in hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Epidemiology of hepatitis B virus infection among pregnant women in Africa: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- Prevalence of chronic viral hepatitis B, D among Mongol migrants in Sweden compared to a sex- and age-matched native Mongol cohort.BMC infectious diseases · 2026Article
- Impact of TNF-α (- 308G>A and - 857 C>T) promoter variants on susceptibility to chronic hepatitis B virus infection in a cohort of Mauritanian patients: pilot study.BMC microbiology · 2026Article
- "The Culturally and Linguistically Diverse Community Is Not Just Minoritised But Ignored": Engaging Culturally and Linguistically Diverse Communities in Australia With Blood-Borne Viruses and Sexually Transmissible Infections Healthcare.Health expectations : an international journal of public participation in health care and health policy · 2025Article
- Diversity and inclusion in chronic hepatitis B randomised controlled trials: A systematic meta-epidemiological review.JHEP reports : innovation in hepatology · 2025Article
- Real-world experience with nucleos(t)ide analogue therapy and patient survival rates in chronic viral hepatitis B treatment centers in Eritrea.Scientific reports · 2025Article
- From need to neglect: Exploring psychological barriers to preventive interventions in pregnancy.PLOS global public health · 2025Article
- Article
- Global burden of liver cirrhosis and other chronic liver diseases caused by specific etiologies from 1990 to 2019.BMC public health · 2024Article
- An Intersectional Approach to Hepatitis B.International journal of environmental research and public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hepatitis B virus disproportionately affects migrant communities in high-income countries, reflecting increased migration from sub-Saharan Africa. Chronic hepatitis B virus is endemic in sub-Saharan Africa, yet the natural history of chronic infection experienced by patients remains incompletely understood, with evidence of variability across genotypes and regions within sub-Saharan Africa. Clinical guidelines recommending treatment thresholds are not specific to sub-Saharan African patients and are based on natural history studies from Western Pacific Asian countries. Access to standard of care treatment is available for sub-Saharan African people with chronic hepatitis B virus infection in high-income countries; however, the evidence base for these treatments was not established in this cohort and areas of uncertainty remain, particularly regarding HCC surveillance and treatment discontinuation. Participation in phase III clinical trials for chronic hepatitis B therapies is almost non-existent amongst sub-Saharan African patients, even when residing in high-income countries that participate in multicentre trials. Engagement with sub-Saharan African patients with chronic hepatitis B in high-income countries is challenging because of the stigma associated with the diagnosis, absence of routine screening systems and the complexities involved in navigating the healthcare system. Nonetheless, improved engagement is critical if we are to achieve global hepatitis B virus elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.